These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 24427139)

  • 1. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.
    Sánchez-Blázquez P; Rodríguez-Muñoz M; Garzón J
    Front Pharmacol; 2014 Jan; 4():169. PubMed ID: 24427139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases.
    Sánchez-Blázquez P; Rodríguez-Muñoz M; Herrero-Labrador R; Burgueño J; Zamanillo D; Garzón J
    Int J Neuropsychopharmacol; 2014 Dec; 17(12):1943-55. PubMed ID: 24485144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.
    Rodríguez-Muñoz M; Sánchez-Blázquez P; Merlos M; Garzón-Niño J
    Oncotarget; 2016 Aug; 7(34):55840-55862. PubMed ID: 27323834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity.
    Vicente-Sánchez A; Sánchez-Blázquez P; Rodríguez-Muñoz M; Garzón J
    Mol Brain; 2013 Oct; 6():42. PubMed ID: 24093505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate.
    Sánchez-Blázquez P; Rodríguez-Muñoz M; Vicente-Sánchez A; Garzón J
    Antioxid Redox Signal; 2013 Nov; 19(15):1766-82. PubMed ID: 23600761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective Effects of Cannabispirenone A against NMDA-Induced Excitotoxicity in Differentiated N2a Cells.
    Thapa S; Nalli Y; Singh A; Singh SK; Ali A
    Oxid Med Cell Longev; 2024; 2024():3530499. PubMed ID: 38855429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?
    Bygrave AM; Kilonzo K; Kullmann DM; Bannerman DM; Kätzel D
    Front Psychiatry; 2019; 10():835. PubMed ID: 31824347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders.
    Rodríguez-Muñoz M; Cortés-Montero E; Pozo-Rodrigálvarez A; Sánchez-Blázquez P; Garzón-Niño J
    Oncotarget; 2015 Nov; 6(34):35458-77. PubMed ID: 26461475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis.
    Sherif MA; Cortes-Briones JA; Ranganathan M; Skosnik PD
    Eur J Neurosci; 2018 Oct; 48(8):2890-2902. PubMed ID: 29247465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAAG, NMDA receptor and psychosis.
    Bergeron R; Coyle JT
    Curr Med Chem; 2012; 19(9):1360-4. PubMed ID: 22304714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.
    Warikoo N; Brunwasser SJ; Benz A; Shu HJ; Paul SM; Lewis M; Doherty J; Quirk M; Piccio L; Zorumski CF; Day GS; Mennerick S
    J Neurosci; 2018 Mar; 38(13):3218-3229. PubMed ID: 29476014
    [No Abstract]   [Full Text] [Related]  

  • 12. N-methyl-D-aspartate receptor hypofunction as a potential contributor to the progression and manifestation of many neurological disorders.
    Dong B; Yue Y; Dong H; Wang Y
    Front Mol Neurosci; 2023; 16():1174738. PubMed ID: 37396784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.
    Snyder MA; Gao WJ
    Schizophr Res; 2020 Mar; 217():60-70. PubMed ID: 30979669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia.
    Holcomb HH; Lahti AC; Medoff DR; Cullen T; Tamminga CA
    Neuropsychopharmacology; 2005 Dec; 30(12):2275-82. PubMed ID: 16034443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia.
    Wu Q; Huang J; Wu R
    Front Neurosci; 2021; 15():641047. PubMed ID: 33912003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The origin of NMDA receptor hypofunction in schizophrenia.
    Nakazawa K; Sapkota K
    Pharmacol Ther; 2020 Jan; 205():107426. PubMed ID: 31629007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
    Pei JC; Hung WL; Lin BX; Shih MH; Lu LY; Luo DZ; Tai HC; Studer V; Min MY; Lai WS
    J Psychopharmacol; 2019 Oct; 33(10):1288-1302. PubMed ID: 31294644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia.
    Gulchina Y; Xu SJ; Snyder MA; Elefant F; Gao WJ
    J Neurochem; 2017 Nov; 143(3):320-333. PubMed ID: 28628228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute NMDA receptor antagonism impairs working memory performance but not attention in rats-Implications for the NMDAr hypofunction theory of schizophrenia.
    Lee J; van den Buuse M; Nithianantharajah J; Jones NC
    Behav Neurosci; 2020 Aug; 134(4):323-331. PubMed ID: 32658524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.